Phone: 404-321-6111 ext. 2546
See also these other websites:
I serve as Assistant Professor in the Scientific Working Group in Reservoirs and Eradication, Laboratory of Biochemical Pharmacology, Department of Pediatrats, Emory University School of Medicine (LOBP), directed by Raymond F. Schinazi, Ph.D., D.Sc. HIV related research focuses on pharmacokinetic (PK), pharmacodynamic (PD), and viral dynamic modeling and simulation to guide preclinical and early clinical development of anti-viral (HIV, HBV and HCV) drugs. Recent research highlights include: PK - cellular biochemical models to study the interplay between the dose of nucleoside inhibitors of reverse transcriptase (NRTI), formation of active metabolites in susceptible tissues, and viral depletion (Hurwitz & Schinazi., Antiviral Res., 2002); allometric PK scaling to derive bio-equivalent doses in experimental animal models and humans (e.g. reverset, Hurwitz, et al., Antivir. Chem. Chemother., 2005); population PK-PD modeling and the conduct of virtual clinical trials in silico, to explore the effect of NRTI dosage regimen on expected virus loads among individuals treated for HIV (e.g. lamivudine, Hurwitz, et al., Antivir. Chem. Chemother., 2008); PK analysis of Phase1 studies on novel NRTI discovered in the LOBP (e.g. Amdoxovir, Hurwitz, et al., Antimicrob. Agents Chemother., 2010); populaton PK-biochemical modeling to derive safer, reduced dosage regimens of older antiretroviral drugs to decrease toxicity without compromizing efficacy e.g., zidovudine (Hurwitz, et al., Antimicrob. Agents Chemother, 2008), and stavudine which is still in use in resource poor settings (Hurwitz & Schinazi, Antiviral Res., 2011).
Drs. Raymond Schinazi, Thomas North, James Nettles, James Kohler, Leda Bassit, Jan Mead